Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer

R. B. Herberman, M. Bordes, P. H. Lambert, H. S. Luthra, R. A. Robins, P. Sizaret, A. Theofilopoulos

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

There have been several reports on the possible value of measurement of circulating immune complexes for the diagnosis of human breast cancer. To begin to evaluate this possibility and the comparability of results among laboratories, a cooperative study was organized under the auspices of the International Agency for Research on Cancer and the National Cancer Institute (NCI) of the United States. Investigators from four laboratories performing assays for immune complexes were sent coded aliquots of serum specimens from the MCI-Mayo Clinic Serum Bank. The serum panel consisted of specimens from 30 patients with breast cancer (including 20 from untreated patients with resectable tumors), 30 preoperative patients with benign breast disease, and 30 normal women. Although some significant differences in levels of immune complexes between cancer patients and controls were seen, none of the assays had sufficient discriminatory capacity to support optimism about the diagnostic value of this approach. To relate the results with immune complexes to those with a widely used cancer marker, the same sera were also tested for levels of carcinoembryonic antigen (CEA). The CEA assay provided significant discrimination between cancer patients and normal donors but did not significantly discriminate between malignant and benign breast disease.

Original languageEnglish (US)
Pages (from-to)569-576
Number of pages8
JournalInternational Journal of Cancer
Volume27
Issue number5
DOIs
StatePublished - 1981

Fingerprint

Antigen-Antibody Complex
Breast Neoplasms
Breast Diseases
Carcinoembryonic Antigen
Neoplasms
Serum
International Agencies
National Cancer Institute (U.S.)
Biomarkers
Research Personnel
Tissue Donors
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Herberman, R. B., Bordes, M., Lambert, P. H., Luthra, H. S., Robins, R. A., Sizaret, P., & Theofilopoulos, A. (1981). Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer. International Journal of Cancer, 27(5), 569-576. https://doi.org/10.1002/ijc.2910270502

Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer. / Herberman, R. B.; Bordes, M.; Lambert, P. H.; Luthra, H. S.; Robins, R. A.; Sizaret, P.; Theofilopoulos, A.

In: International Journal of Cancer, Vol. 27, No. 5, 1981, p. 569-576.

Research output: Contribution to journalArticle

Herberman, RB, Bordes, M, Lambert, PH, Luthra, HS, Robins, RA, Sizaret, P & Theofilopoulos, A 1981, 'Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer', International Journal of Cancer, vol. 27, no. 5, pp. 569-576. https://doi.org/10.1002/ijc.2910270502
Herberman, R. B. ; Bordes, M. ; Lambert, P. H. ; Luthra, H. S. ; Robins, R. A. ; Sizaret, P. ; Theofilopoulos, A. / Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer. In: International Journal of Cancer. 1981 ; Vol. 27, No. 5. pp. 569-576.
@article{2df97dbd7105489ab5bdd96d784df27e,
title = "Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer",
abstract = "There have been several reports on the possible value of measurement of circulating immune complexes for the diagnosis of human breast cancer. To begin to evaluate this possibility and the comparability of results among laboratories, a cooperative study was organized under the auspices of the International Agency for Research on Cancer and the National Cancer Institute (NCI) of the United States. Investigators from four laboratories performing assays for immune complexes were sent coded aliquots of serum specimens from the MCI-Mayo Clinic Serum Bank. The serum panel consisted of specimens from 30 patients with breast cancer (including 20 from untreated patients with resectable tumors), 30 preoperative patients with benign breast disease, and 30 normal women. Although some significant differences in levels of immune complexes between cancer patients and controls were seen, none of the assays had sufficient discriminatory capacity to support optimism about the diagnostic value of this approach. To relate the results with immune complexes to those with a widely used cancer marker, the same sera were also tested for levels of carcinoembryonic antigen (CEA). The CEA assay provided significant discrimination between cancer patients and normal donors but did not significantly discriminate between malignant and benign breast disease.",
author = "Herberman, {R. B.} and M. Bordes and Lambert, {P. H.} and Luthra, {H. S.} and Robins, {R. A.} and P. Sizaret and A. Theofilopoulos",
year = "1981",
doi = "10.1002/ijc.2910270502",
language = "English (US)",
volume = "27",
pages = "569--576",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer

AU - Herberman, R. B.

AU - Bordes, M.

AU - Lambert, P. H.

AU - Luthra, H. S.

AU - Robins, R. A.

AU - Sizaret, P.

AU - Theofilopoulos, A.

PY - 1981

Y1 - 1981

N2 - There have been several reports on the possible value of measurement of circulating immune complexes for the diagnosis of human breast cancer. To begin to evaluate this possibility and the comparability of results among laboratories, a cooperative study was organized under the auspices of the International Agency for Research on Cancer and the National Cancer Institute (NCI) of the United States. Investigators from four laboratories performing assays for immune complexes were sent coded aliquots of serum specimens from the MCI-Mayo Clinic Serum Bank. The serum panel consisted of specimens from 30 patients with breast cancer (including 20 from untreated patients with resectable tumors), 30 preoperative patients with benign breast disease, and 30 normal women. Although some significant differences in levels of immune complexes between cancer patients and controls were seen, none of the assays had sufficient discriminatory capacity to support optimism about the diagnostic value of this approach. To relate the results with immune complexes to those with a widely used cancer marker, the same sera were also tested for levels of carcinoembryonic antigen (CEA). The CEA assay provided significant discrimination between cancer patients and normal donors but did not significantly discriminate between malignant and benign breast disease.

AB - There have been several reports on the possible value of measurement of circulating immune complexes for the diagnosis of human breast cancer. To begin to evaluate this possibility and the comparability of results among laboratories, a cooperative study was organized under the auspices of the International Agency for Research on Cancer and the National Cancer Institute (NCI) of the United States. Investigators from four laboratories performing assays for immune complexes were sent coded aliquots of serum specimens from the MCI-Mayo Clinic Serum Bank. The serum panel consisted of specimens from 30 patients with breast cancer (including 20 from untreated patients with resectable tumors), 30 preoperative patients with benign breast disease, and 30 normal women. Although some significant differences in levels of immune complexes between cancer patients and controls were seen, none of the assays had sufficient discriminatory capacity to support optimism about the diagnostic value of this approach. To relate the results with immune complexes to those with a widely used cancer marker, the same sera were also tested for levels of carcinoembryonic antigen (CEA). The CEA assay provided significant discrimination between cancer patients and normal donors but did not significantly discriminate between malignant and benign breast disease.

UR - http://www.scopus.com/inward/record.url?scp=0019475240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019475240&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910270502

DO - 10.1002/ijc.2910270502

M3 - Article

VL - 27

SP - 569

EP - 576

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -